Vicore Pharma Holding AB (OSTO:VICO) Tariff Resilience Score: 0/10 (As of Jul. 04, 2026)


OSTO:VICO Vicore Pharma Holding AB OSTO:VICO
30 GF Score
Price kr13.44
! 5 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB Tariff Resilience Score?

Vicore Pharma Holding AB has the Tariff Resilience Score of 0, which implies that the company might have .

Vicore Pharma Holding AB has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Vicore Pharma Holding AB might have .

Vicore Pharma Holding AB  (OSTO:VICO) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Vicore Pharma Holding AB Tariff Resilience Score Related Terms

OSTO:VICO
30GF Score
Vicore Pharma Holding AB OSTO:VICO
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vicore Pharma Holding AB Business Description

Other Exchanges 6Y4:Germany
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
30GF Score

Get the complete analysis for OSTO:VICO

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr13.44
Price